Artivion Inc AORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
-
Artivion to Participate in the 2026 Truist Securities MedTech Conference
-
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
-
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
-
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
-
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $24.11
- Day Range
- $23.66–24.23
- 52-Week Range
- $19.16–48.25
- Bid/Ask
- $23.00 / $26.00
- Shares Outstanding
- 48.54M
- Market Cap
- $1.17B
- Volume/Avg
- 333,271 / 747,954
Key Statistics
- Price/Earnings (Normalized)
- 37.63
- Price/Sales
- 2.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,800
- Website
- https://www.artivion.com
Valuation
|
Metric
|
AORT
|
|---|---|
Price/Earnings (Normalized) | 37.63 |
Price/Book Value | 2.63 |
Price/Sales | 2.61 |
Price/Cash Flow | 16.54 |
Price/Earnings
AORT
Financial Strength
|
Metric
|
AORT
|
|---|---|
Quick Ratio | 1.74 |
Current Ratio | 3.86 |
Interest Coverage | 1.68 |
Quick Ratio
AORT
Profitability
|
Metric
|
AORT
|
|---|---|
Return on Assets (Normalized) | 3.69% |
Return on Equity (Normalized) | 7.66% |
Return on Invested Capital (Normalized) | 6.83% |
Return on Assets
AORT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Y$FdK> | LOCK|^BYb | $164B | |||
| Stryker Corp
SYK
| LOCK|LK&znFn | LOCK|hS | $126B | |||
| Medtronic PLC
MDT
| LOCK|@S#y>< | LOCK|!@yP | $107B | |||
| Boston Scientific Corp
BSX
| LOCK|<m&#^B | LOCK|%@Bz^ | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|mr&PQ<?Q | LOCK|Tl@j# | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|>VDM&Zb | LOCK|@< | $29B | |||
| DexCom Inc
DXCM
| LOCK|&k&sWY$^ | LOCK|j$DMy | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|v# | LOCK|%HG | $27B | |||
| Steris PLC
STE
| LOCK|GjQ^@q | LOCK|@%!m | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|CyrTJL#J | LOCK|#R | $18B |
United States